OverviewSuggest Edit

TCR , Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR was founded by MPM Capital and has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
TypePublic
Founded2015
HQCambridge, MA, US
Websitetcr2.com

Latest Updates

Employees (est.) (Feb 2019)44(+5%)
Job Openings39
Share Price (Sept 2021)$18.2
Cybersecurity ratingBMore

Key People/Management at TCR2 Therapeutics

Garry Menzel

Garry Menzel

President and Chief Executive Officer
Alfonso Quintás Cardama

Alfonso Quintás Cardama

Chief Medical Officer
Robert Hofmeister

Robert Hofmeister

Chief Scientific Officer
Angela Justice

Angela Justice

Chief People Officer
Ian Somaiya

Ian Somaiya

Chief Financial Officer
Robert Tighe

Robert Tighe

Vice President of Translational Research
Show more

TCR2 Therapeutics Office Locations

TCR2 Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
100 Binney St #710
Show all (1)

TCR2 Therapeutics Financials and Metrics

TCR2 Therapeutics Revenue

USD

Net income (Q1, 2021)

(21.5m)

EBIT (Q1, 2021)

(21.6m)

Market capitalization (9-Sept-2021)

694.6m

Closing stock price (9-Sept-2021)

18.2

Cash (31-Mar-2021)

218.3m

EV

511.3m
TCR2 Therapeutics's current market capitalization is $694.6 m.
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

General and administrative expense

2.3m3.6m13.9m16.7m

R&D expense

7.7m9.6m37.5m52.0m

Operating expense total

9.9m13.2m51.4m68.7m

EBIT

(9.9m)(13.1m)(51.4m)(68.7m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

2.9m3.3m3.5m4.3m3.8m5.7m

R&D expense

7.9m8.8m11.4m12.0m12.9m15.9m

Operating expense total

10.8m12.1m14.9m16.2m16.7m21.6m

EBIT

(10.8m)(12.1m)(14.9m)(16.2m)(16.7m)(21.6m)
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Cash

8.0m19.8m65.3m94.2m

Prepaid Expenses

975.0k892.0k5.1m7.6m

Current Assets

17.3m20.7m163.2m235.5m

PP&E

936.0k1.0m4.9m10.0m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

46.4m41.0m49.3m31.1m49.7m218.3m

Prepaid Expenses

3.9m6.1m5.6m6.8m9.0m9.7m

Current Assets

165.6m175.7m166.6m133.0m133.8m343.0m

PP&E

1.9m3.2m4.5m5.2m6.0m51.8m
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Net Income

(9.9m)(13.1m)(47.6m)(67.1m)

Depreciation and Amortization

220.0k298.0k862.0k1.6m

Accounts Payable

76.0k(101.0k)(179.0k)451.0k

Cash From Operating Activities

(9.4m)(12.0m)(41.4m)(56.7m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(9.9m)(21.0m)(34.8m)(15.5m)(31.8m)(21.5m)

Depreciation and Amortization

135.0k300.0k558.0k306.0k673.0k513.0k

Accounts Payable

(401.0k)180.0k489.0k603.0k29.0k1.7m

Cash From Operating Activities

(10.8m)(21.0m)(31.0m)(16.4m)(32.4m)(19.9m)
USDFY, 2016

Financial Leverage

1.1 x
Show all financial metrics

TCR2 Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
TRUC Securities Corporation
TRUCS Therapeutics Limited

TCR2 Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

TCR2 Therapeutics Online and Social Media Presence

Embed Graph

TCR2 Therapeutics News and Updates

Thinking about buying stock in Tcr2 Therapeutics, Inovio Pharmaceuticals, BioLineRx, Plug Power, or Arbutus Biopharma?

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TCRR, INO, BLRX, PLUG, and ABUS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

TCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast

CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (TCR2) (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will release results for the first quarter …

TCR2 Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., March 28, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced that preclinical data on its lead...

TCR2 Therapeutics Announces Exercise of Over-Allotment Option

CAMBRIDGE, Mass., Feb. 26, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced that the underwriters of its recent...

TCR2 Therapeutics Announces Pricing of Initial Public Offering of Common Stock

CAMBRIDGE, Mass., Feb. 13, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced the pricing of the Company's initial...

TCR2 Therapeutics Launches Proposed Initial Public Offering

CAMBRIDGE, Mass., Feb. 1, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer, today announced that it has launched an underwritten initial public offering...
Show more

TCR2 Therapeutics Blogs

TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Content Import Thu, 08/05/2021 - 06:45 TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Aug 05, 2021 This release is a backfill f…

TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline

CAMBRIDGE, Mass. , March 10, 2021 (GLOBE NEWSWIRE) -- TCR 2   Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that three e-poster presentations featuring new clinical data from the

TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors

CAMBRIDGE, Mass. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- TCR 2   Therapeutics Inc. (Nasdaq: TCRR) (“TCR 2 ” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Shawn Tomasello to its

TCR² Therapeutics to Participate in Two Upcoming Conferences in September

TCR² Therapeutics to Participate in Two Upcoming Conferences in September Katherine.Howe… Tue, 09/08/2020 - 08:30 TCR² Therapeutics to Participate in Two Upcoming Conferences in September Sep 08, 2020 This release is a backfill from a News Wire Genera…

TCR2 Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

TCR2 Therapeutics to Present at the Wedbush PacGrow Healthcare Conference Katherine.Howe… Thu, 08/06/2020 - 16:38 TCR2 Therapeutics to Present at the Wedbush PacGrow Healthcare Conference Aug 06, 2020 This release is a backfill from a News Wire General …

TCR² Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , July 28, 2020 (GLOBE NEWSWIRE) -- TCR 2   Therapeutics Inc. (Nasdaq: TCRR) (“TCR 2 ” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the pricing of an underwritten public
Show more

TCR2 Therapeutics Frequently Asked Questions

  • When was TCR2 Therapeutics founded?

    TCR2 Therapeutics was founded in 2015.

  • Who are TCR2 Therapeutics key executives?

    TCR2 Therapeutics's key executives are Garry Menzel, Alfonso Quintás Cardama and Robert Hofmeister.

  • How many employees does TCR2 Therapeutics have?

    TCR2 Therapeutics has 44 employees.

  • Who are TCR2 Therapeutics competitors?

    Competitors of TCR2 Therapeutics include Travecta Therapeutics, PolyPid and VBI Vaccines.

  • Where is TCR2 Therapeutics headquarters?

    TCR2 Therapeutics headquarters is located at 100 Binney St #710, Cambridge.

  • Where are TCR2 Therapeutics offices?

    TCR2 Therapeutics has an office in Cambridge.

  • How many offices does TCR2 Therapeutics have?

    TCR2 Therapeutics has 1 office.